Promising pCR Rates with Neoadjuvant Durvalumab Plus Platinum-based Chemotherapy Combined with ADC for Patients with Resectable NSCLC By Ogkologos - July 29, 2025 470 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the NeoCOAST-2 study Source RELATED ARTICLESMORE FROM AUTHOR Advanced and metastatic prostate cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up PAXG Significantly Improves EFS Compared with mFOLFIRINOX in Patients with Resectable or Borderline Resectable Pancreatic Ductal Adenocarcinoma EMA Recommends Extension of Therapeutic Indications for Retifanlimab MOST POPULAR Insulin Resistance May Contribute to Poorer Breast Cancer Outcomes, Study Says June 2, 2020 “The power of science”: HPV vaccine proven to dramatically reduce cervical... November 3, 2021 FDA Approves Revumenib for Relapsed or Refractory Acute Myeloid Leukaemia with... October 30, 2025 18-Year-Old Jaguar at Akron Zoo Diagnosed with Breast Cancer September 6, 2019 Load more HOT NEWS FDA Grants Accelerated Approval to Pembrolizumab for Locally Recurrent Unresectable or... Trial Results Confirm Effectiveness of Atezolizumab Against a Rare Sarcoma How I Coped With My Own Cancer Diagnoses As an Oncologist Professional Runner and Mom of Two Shares Photo Of Belly Cavity...
